{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:13:12Z","timestamp":1793679192412,"version":"4.5.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2010PWNJXK"],"award-info":[{"award-number":["2010PWNJXK"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"IMI","award":["115372"],"award-info":[{"award-number":["115372"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13195-017-0276-4","type":"journal-article","created":{"date-parts":[[2017,7,27]],"date-time":"2017-07-27T07:10:19Z","timestamp":1501139419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":102,"title":["Differential role of CSF fatty acid binding protein 3, \u03b1-synuclein, and Alzheimer\u2019s disease core biomarkers in Lewy body disorders and Alzheimer\u2019s dementia"],"prefix":"10.1186","volume":"9","author":[{"given":"Davide","family":"Chiasserini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Biscetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Eusebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Salvadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Frattini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Simoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"De Roeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Tambasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Stoops","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Vanderstichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiaan","family":"Engelborghs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brit","family":"Mollenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Calabresi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"276_CR1","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/ana.22615","volume":"70","author":"M Jucker","year":"2011","unstructured":"Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011;70:532\u201340.","journal-title":"Ann Neurol."},{"key":"276_CR2","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/j.1582-4934.2011.01507.x","volume":"16","author":"KA Jellinger","year":"2012","unstructured":"Jellinger KA. Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med. 2012;16:1166\u201383.","journal-title":"J Cell Mol Med."},{"key":"276_CR3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/alzrt50","volume":"2","author":"PJ McMillan","year":"2010","unstructured":"McMillan PJ, Leverenz JB. From model system to clinical medicine: pathophysiologic links of common proteinopathies. Alzheimers Res Ther. 2010;2:26.","journal-title":"Alzheimers Res Ther."},{"key":"276_CR4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1136\/jnnp.72.5.602","volume":"72","author":"EK Doubleday","year":"2002","unstructured":"Doubleday EK, Snowden JS, Varma AR, Neary D. Qualitative performance characteristics differentiate dementia with Lewy bodies and Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2002;72:602\u20137.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"276_CR5","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1002\/mds.21507","volume":"22","author":"M Emre","year":"2007","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord. 2007;22:1689\u2013707. quiz 1837.","journal-title":"Mov Disord."},{"key":"276_CR6","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/jnen\/64.2.156","volume":"64","author":"I Mikolaenko","year":"2005","unstructured":"Mikolaenko I, Pletnikova O, Kawas CH, O\u2019Brien R, Resnick SM, Crain B, et al. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol. 2005;64:156\u201362.","journal-title":"J Neuropathol Exp Neurol."},{"key":"276_CR7","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/jnen\/nlw070","volume":"75","author":"DH Hepp","year":"2016","unstructured":"Hepp DH, Vergoossen DLE, Huisman E, Lemstra AW, Netherlands Brain Bank, Berendse HW, et al. Distribution and load of amyloid-\u03b2 pathology in Parkinson disease and dementia with Lewy bodies. J Neuropathol Exp Neurol. 2016;75:936\u201345.","journal-title":"J Neuropathol Exp Neurol"},{"key":"276_CR8","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1001\/jamaneurol.2016.3338","volume":"73","author":"SN Gomperts","year":"2016","unstructured":"Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, et al. Tau positron emission tomographic imaging in the Lewy body diseases. JAMA Neurol. 2016;73:1334\u201341.","journal-title":"JAMA Neurol."},{"key":"276_CR9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jagp.2013.03.001","volume":"23","author":"P Donaghy","year":"2015","unstructured":"Donaghy P, Thomas AJ, O\u2019Brien JT. Amyloid PET imaging in Lewy body disorders. Am J Geriatr Psychiatry. 2015;23:23\u201337.","journal-title":"Am J Geriatr Psychiatry."},{"key":"276_CR10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00401-012-0983-7","volume":"124","author":"JB Toledo","year":"2012","unstructured":"Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, et al. CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol. 2012;124:23\u201335.","journal-title":"Acta Neuropathol."},{"key":"276_CR11","doi-asserted-by":"crossref","first-page":"813","DOI":"10.3233\/JAD-141986","volume":"45","author":"H Struyfs","year":"2015","unstructured":"Struyfs H, Van Broeck B, Timmers M, Fransen E, Sleegers K, Van Broeckhoven C, et al. Diagnostic accuracy of cerebrospinal fluid amyloid-\u03b2 isoforms for early and differential dementia diagnosis. J Alzheimers Dis. 2015;45:813\u201322.","journal-title":"J Alzheimers Dis."},{"key":"276_CR12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3389\/fnagi.2014.00053","volume":"6","author":"L Parnetti","year":"2014","unstructured":"Parnetti L, Farotti L, Eusebi P, Chiasserini D, De Carlo C, Giannandrea D, et al. Differential role of CSF \u03b1-synuclein species, tau, and A\u03b242 in Parkinson\u2019s disease. Front Aging Neurosci. 2014;6:53.","journal-title":"Front Aging Neurosci."},{"key":"276_CR13","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1212\/WNL.0000000000000425","volume":"82","author":"G Alves","year":"2014","unstructured":"Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, F\u00f8rland MG, et al. CSF A\u03b242 predicts early-onset dementia in Parkinson disease. Neurology. 2014;82:1784\u201390.","journal-title":"Neurology."},{"key":"276_CR14","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/mds.23670","volume":"26","author":"L Parnetti","year":"2011","unstructured":"Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, de Carlo C, Qureshi MM, et al. Cerebrospinal fluid tau\/\u03b1-synuclein ratio in Parkinson\u2019s disease and degenerative dementias. Mov Disord. 2011;26:1428\u201335.","journal-title":"Mov Disord."},{"key":"276_CR15","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/alzrt255","volume":"6","author":"O Hansson","year":"2014","unstructured":"Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, et al. Levels of cerebrospinal fluid \u03b1-synuclein oligomers are increased in Parkinson\u2019s disease with dementia and dementia with Lewy bodies compared to Alzheimer\u2019s disease. Alzheimers Res Ther. 2014;6:25.","journal-title":"Alzheimers Res Ther."},{"key":"276_CR16","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.parkreldis.2013.06.008","volume":"19","author":"JM Yeo","year":"2013","unstructured":"Yeo JM, Green A, Pal S. The diagnostic utility of cerebrospinal fluid \u03b1-synuclein analysis in dementia with Lewy bodies\u2014a systematic review and meta-analysis. Parkinsonism Relat Disord. 2013;19:851\u20138.","journal-title":"Parkinsonism Relat Disord."},{"key":"276_CR17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/mds.26754","volume":"31","author":"NK Majbour","year":"2016","unstructured":"Majbour NK, Vaikath NN, Eusebi P, Chiasserini D, Ardah M, Varghese S, et al. Longitudinal changes in CSF \u03b1-synuclein species reflect Parkinson\u2019s disease progression. Mov Disord. 2016;31:1535\u201342.","journal-title":"Mov Disord."},{"key":"276_CR18","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/mds.25772","volume":"29","author":"L Parnetti","year":"2014","unstructured":"Parnetti L, Chiasserini D, Persichetti E, Eusebi P, Varghese S, Qureshi MM, et al. Cerebrospinal fluid lysosomal enzymes and \u03b1-synuclein in Parkinson\u2019s disease. Mov Disord. 2014;29:1019\u201327.","journal-title":"Mov Disord."},{"key":"276_CR19","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/archneurol.2012.1654","volume":"69","author":"S Hall","year":"2012","unstructured":"Hall S, \u00d6hrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, et al. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and\/or parkinsonian disorders. Arch Neurol. 2012;69:1445\u201352.","journal-title":"Arch Neurol."},{"key":"276_CR20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2014.05.052","volume":"343","author":"HP Vranov\u00e1","year":"2014","unstructured":"Vranov\u00e1 HP, H\u00e9nykov\u00e1 E, Kaiserov\u00e1 M, Men\u0161\u00edkov\u00e1 K, Va\u0161t\u00edk M, Mare\u0161 J, et al. Tau protein, \u03b2-amyloid1\u201342 and clusterin CSF levels in the differential diagnosis of parkinsonian syndrome with dementia. J Neurol Sci. 2014;343:120\u20134.","journal-title":"J Neurol Sci."},{"key":"276_CR21","doi-asserted-by":"crossref","unstructured":"Struyfs H, Niemantsverdriet E, Goossens J, Fransen E, Martin JJ, De Deyn PP, et al. Cerebrospinal fluid P-tau181P: biomarker for improved differential dementia diagnosis. Front Neurol. 2015;6:138.","DOI":"10.3389\/fneur.2015.00138"},{"key":"276_CR22","doi-asserted-by":"crossref","first-page":"6350","DOI":"10.1021\/bi047292r","volume":"44","author":"EJ Murphy","year":"2005","unstructured":"Murphy EJ, Owada Y, Kitanaka N, Kondo H, Glatz JF. Brain arachidonic acid incorporation is decreased in heart fatty acid binding protein gene-ablated mice. Biochemistry. 2005;44:6350\u201360.","journal-title":"Biochemistry."},{"key":"276_CR23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1385\/JMN:16:2-3:133","volume":"16","author":"JH Veerkamp","year":"2001","unstructured":"Veerkamp JH, Zimmerman AW. Fatty acid-binding proteins of nervous tissue. J Mol Neurosci. 2001;16:133\u201342.","journal-title":"J Mol Neurosci."},{"key":"276_CR24","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1523\/JNEUROSCI.4140-09.2010","volume":"30","author":"N Shioda","year":"2010","unstructured":"Shioda N, Yamamoto Y, Watanabe M, Binas B, Owada Y, Fukunaga K. Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain. J Neurosci. 2010;30:3146\u201355.","journal-title":"J Neurosci."},{"key":"276_CR25","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/pmic.200300478","volume":"3","author":"E Guillaume","year":"2003","unstructured":"Guillaume E, Zimmermann C, Burkhard PR, Hochstrasser DF, Sanchez JC. A potential cerebrospinal fluid and plasmatic marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics. 2003;3:1495\u20139.","journal-title":"Proteomics."},{"key":"276_CR26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1159\/000105157","volume":"4","author":"B Mollenhauer","year":"2007","unstructured":"Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, et al. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis. 2007;4:366\u201375.","journal-title":"Neurodegener Dis."},{"key":"276_CR27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s00406-013-0405-4","volume":"263","author":"LH Guo","year":"2013","unstructured":"Guo LH, Alexopoulos P, Perneczky R. Heart-type fatty acid binding protein and vascular endothelial growth factor: cerebrospinal fluid biomarker candidates for Alzheimer\u2019s disease. Eur Arch Psychiatry Clin Neurosci. 2013;263:553\u201360.","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"276_CR28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3233\/JAD-2011-110566","volume":"27","author":"M Bjerke","year":"2011","unstructured":"Bjerke M, Zetterberg H, Edman \u00c5, Blennow K, Wallin A, Andreasson U. Cerebrospinal fluid matrix metalloproteinases and tissue inhibitor of metalloproteinases in combination with subcortical and cortical biomarkers in vascular dementia and Alzheimer\u2019s disease. J Alzheimers Dis. 2011;27:665\u201376.","journal-title":"J Alzheimers Dis."},{"key":"276_CR29","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.biopsych.2013.11.032","volume":"75","author":"O Harari","year":"2014","unstructured":"Harari O, Cruchaga C, Kauwe JSK, Ainscough BJ, Bales K, Pickering EH, et al. Phosphorylated tau-A\u03b242 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer\u2019s disease in multiplex immunoassay panels of cerebrospinal fluid. Biol Psychiatry. 2014;75:723\u201331.","journal-title":"Biol Psychiatry."},{"key":"276_CR30","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3233\/JAD-2010-101293","volume":"22","author":"D Chiasserini","year":"2010","unstructured":"Chiasserini D, Parnetti L, Andreasson U, Zetterberg H, Giannandrea D, Calabresi P, et al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer\u2019s disease. J Alzheimers Dis. 2010;22:1281\u20138.","journal-title":"J Alzheimers Dis."},{"key":"276_CR31","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3233\/JAD-150525","volume":"49","author":"M Bjerke","year":"2015","unstructured":"Bjerke M, Kern S, Blennow K, Zetterberg H, Waern M, B\u00f6rjesson-Hanson A, et al. Cerebrospinal fluid fatty acid-binding protein 3 is related to dementia development in a population-based sample of older adult women followed for 8\u00a0years. J Alzheimers Dis. 2015;49:733\u201341.","journal-title":"J Alzheimers Dis."},{"key":"276_CR32","doi-asserted-by":"crossref","first-page":"18957","DOI":"10.1074\/jbc.M113.527341","volume":"289","author":"N Shioda","year":"2014","unstructured":"Shioda N, Yabuki Y, Kobayashi Y, Onozato M, Owada Y, Fukunaga K. FABP3 protein promotes \u03b1-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity. J Biol Chem. 2014;289:18957\u201365.","journal-title":"J Biol Chem."},{"key":"276_CR33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2011;7:263\u20139.","journal-title":"Alzheimer\u2019s Dement."},{"key":"276_CR34","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55:181\u20134.","journal-title":"J Neurol Neurosurg Psychiatry."},{"key":"276_CR35","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/mds.10459","volume":"18","author":"I Litvan","year":"2003","unstructured":"Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord. 2003;18:467\u201386.","journal-title":"Mov Disord."},{"key":"276_CR36","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1212\/01.wnl.0000187889.17253.b1","volume":"65","author":"IG McKeith","year":"2005","unstructured":"McKeith IG, Dickson DW, Lowe J, Emre M, O\u2019Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863\u201372.","journal-title":"Neurology."},{"key":"276_CR37","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1212\/WNL.0b013e3181c47cc2","volume":"73","author":"CE Teunissen","year":"2009","unstructured":"Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology. 2009;73:1914\u201322.","journal-title":"Neurology."},{"key":"276_CR38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-2011-111349","volume":"29","author":"L Parnetti","year":"2012","unstructured":"Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, et al. Performance of A\u03b21\u201340, A\u03b21\u201342, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimer\u2019s Dis. 2012;29:229\u201338.","journal-title":"J Alzheimer\u2019s Dis."},{"key":"276_CR39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3233\/JAD-160298","volume":"54","author":"D Chiasserini","year":"2016","unstructured":"Chiasserini D, Biscetti L, Farotti L, Eusebi P, Salvadori N, Lisetti V, et al. Performance evaluation of an automated ELISA system for Alzheimer\u2019s disease detection in clinical routine. J Alzheimers Dis. 2016;54:55\u201367.","journal-title":"J Alzheimers Dis."},{"issue":"7 Suppl","key":"276_CR40","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jalz.2016.06.1330","volume":"12","author":"E Stoops","year":"2016","unstructured":"Stoops E, Majbour N, Mauroo K, Demeyer L, Lashuel H, Trojanowski JQ, et al. Performance evaluation of new absorbance-based ELISAs for measuring different \u03b1-synuclein (A-SYN) species in CSF and plasma [abstract]. Alzheimer\u2019s Dement. 2016;12(7 Suppl):677\u20138.","journal-title":"Alzheimer\u2019s Dement"},{"key":"276_CR41","unstructured":"R Core Development Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014. p. 409. Available from: http:\/\/www.r-project.org\/ . Accessed 2 Feb 2017."},{"key":"276_CR42","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer\u2019s disease: the IWG-2 criteria. Lancet Neurol. 2014;13:614\u201329.","journal-title":"Lancet Neurol."},{"key":"276_CR43","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1212\/WNL.0b013e31823ed0f0","volume":"78","author":"NSM Schoonenboom","year":"2012","unstructured":"Schoonenboom NSM, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM. Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology. 2012;78:47\u201354.","journal-title":"Neurology."},{"key":"276_CR44","first-page":"761571","volume":"2010","author":"M Bibl","year":"2010","unstructured":"Bibl M, Esselmann H, Lewczuk P, Trenkwalder C, Otto M, Kornhuber J, et al. Combined analysis of CSF tau, A\u03b242, A\u03b21\u201342% and A\u03b21\u201340ox% in Alzheimer\u2019s disease, dementia with Lewy bodies and Parkinson\u2019s disease dementia. Int J Alzheimers Dis. 2010;2010:761571.","journal-title":"Int J Alzheimers Dis."},{"key":"276_CR45","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s100720170055","volume":"22","author":"L Parnetti","year":"2001","unstructured":"Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated tau is a possible marker for discriminating Alzheimer\u2019s disease from dementia with Lewy bodies. Neurol Sci. 2001;22:77\u20138.","journal-title":"Neurol Sci."},{"key":"276_CR46","doi-asserted-by":"crossref","unstructured":"Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S. Improved discrimination of autopsy-confirmed Alzheimer\u2019s disease (AD) from non-AD dementias using CSF P-tau181P. Neurochem Int. 2009;55:214\u20138.","DOI":"10.1016\/j.neuint.2009.02.017"},{"key":"276_CR47","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00702-014-1226-y","volume":"121","author":"W Tang","year":"2014","unstructured":"Tang W, Huang Q, Yao YY, Wang Y, Le Wu Y, Wang ZY. Does CSF p-tau181 help to discriminate Alzheimer\u2019s disease from other dementias and mild cognitive impairment? A meta-analysis of the literature. J Neural Transm. 2014;121:1541\u201353.","journal-title":"J Neural Transm."},{"key":"276_CR48","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/mds.22594","volume":"24","author":"Y Compta","year":"2009","unstructured":"Compta Y, Mart\u00ed MJ, Ibarretxe-Bilbao N, Junqu\u00e9 C, Valldeoriola F, Mu\u00f1oz E, et al. Cerebrospinal tau, phospho-tau, and \u03b2-amyloid and neuropsychological functions in Parkinson\u2019s disease. Mov Disord. 2009;24:2203\u201310.","journal-title":"Mov Disord."},{"issue":"5 Suppl","key":"276_CR49","doi-asserted-by":"crossref","first-page":"S290","DOI":"10.1016\/j.jalz.2013.10.004","volume":"10","author":"S Slaets","year":"2014","unstructured":"Slaets S, Vanmechelen E, Le Bastard N, Decraemer H, Vandijck M, Martin JJ, et al. Increased CSF \u03b1-synuclein levels in Alzheimer\u2019s disease: correlation with tau levels. Alzheimer\u2019s Dement. 2014;10(5 Suppl):S290\u20138.","journal-title":"Alzheimer\u2019s Dement"},{"key":"276_CR50","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00415-016-8259-0","volume":"263","author":"F Llorens","year":"2016","unstructured":"Llorens F, Schmitz M, Varges D, Kruse N, Gotzmann N, Gmitterov\u00e1 K, et al. Cerebrospinal \u03b1-synuclein in \u03b1-synuclein aggregation disorders: tau\/\u03b1-synuclein ratio as potential biomarker for dementia with Lewy bodies. J Neurol. 2016;263:2271\u20137.","journal-title":"J Neurol."},{"key":"276_CR51","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/bmm.15.107","volume":"10","author":"L Parnetti","year":"2016","unstructured":"Parnetti L, Cicognola C, Eusebi P, Chiasserini D. Value of cerebrospinal fluid \u03b1-synuclein species as biomarker in Parkinson\u2019s diagnosis and prognosis. Biomark Med. 2016;10:35\u201349.","journal-title":"Biomark Med."},{"key":"276_CR52","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/nrneurol.2013.10","volume":"9","author":"L Parnetti","year":"2013","unstructured":"Parnetti L, Castrioto A, Chiasserini D, Persichetti E, Tambasco N, El-Agnaf O, et al. Cerebrospinal fluid biomarkers in Parkinson disease. Nat Rev Neurol. 2013;9:131\u201340.","journal-title":"Nat Rev Neurol."},{"key":"276_CR53","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1016\/j.neurobiolaging.2015.05.003","volume":"36","author":"N Kruse","year":"2015","unstructured":"Kruse N, Persson S, Alcolea D, Bahl JMC, Baldeiras I, Capello E, et al. Validation of a quantitative cerebrospinal fluid \u03b1-synuclein assay in a European-wide interlaboratory study. Neurobiol Aging. 2015;36:2587\u201396.","journal-title":"Neurobiol Aging."},{"key":"276_CR54","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neulet.2008.11.015","volume":"450","author":"A \u00d6hrfelt","year":"2009","unstructured":"\u00d6hrfelt A, Grognet P, Andreasen N, Wallin A, Vanmechelen E, Blennow K, et al. Cerebrospinal fluid \u03b1-synuclein in neurodegenerative disorders\u2014a marker of synapse loss? Neurosci Lett. 2009;450:332\u20135.","journal-title":"Neurosci Lett."},{"key":"276_CR55","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s00401-013-1148-z","volume":"126","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Korff A, Shaw LM, Trojanowski JQ, Zhang J. CSF \u03b1-synuclein improves diagnostic and prognostic performance of CSF tau and A\u03b2 in Alzheimer\u2019s disease. Acta Neuropathol. 2013;126:683\u201397.","journal-title":"Acta Neuropathol."},{"key":"276_CR56","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.3233\/JAD-141287","volume":"43","author":"RS Mackin","year":"2015","unstructured":"Mackin RS, Insel P, Zhang J, Mohlenhoff B, Galasko D, Weiner M, et al. Cerebrospinal fluid \u03b1-synuclein and Lewy body-like symptoms in normal controls, mild cognitive impairment, and Alzheimer\u2019s disease. J Alzheimers Dis. 2015;43:1007\u201316.","journal-title":"J Alzheimers Dis."},{"key":"276_CR57","doi-asserted-by":"crossref","first-page":"40263","DOI":"10.1038\/srep40263","volume":"7","author":"NK Majbour","year":"2017","unstructured":"Majbour NK, Chiasserini D, Vaikath NN, Eusebi P, Tokuda T, van de Berg W, et al. Increased levels of CSF total but not oligomeric or phosphorylated forms of \u03b1-synuclein in patients diagnosed with probable Alzheimer\u2019s disease. Sci Rep. 2017;7:40263.","journal-title":"Sci Rep."},{"key":"276_CR58","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.neulet.2004.07.061","volume":"370","author":"P Steinacker","year":"2004","unstructured":"Steinacker P, Mollenhauer B, Bibl M, Cepek L, Esselmann H, Brechlin P, et al. Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett. 2004;370:36\u20139.","journal-title":"Neurosci Lett."},{"key":"276_CR59","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U, \u00d6hrfelt A, Portelius E, Bjerke M, et al. CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15:673\u201384.","journal-title":"Lancet Neurol."},{"key":"276_CR60","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/978-3-211-85578-2_65","volume":"102","author":"ER Zanier","year":"2008","unstructured":"Zanier ER, Longhi L, Fiorini M, Cracco L, Bersano A, Zoerle T, et al. Increased levels of CSF heart-type fatty acid-binding protein and tau protein after aneurysmal subarachnoid hemorrhage. Acta Neurochir Suppl. 2008;102:339\u201343.","journal-title":"Acta Neurochir Suppl."},{"key":"276_CR61","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3233\/JAD-121384","volume":"34","author":"B Olsson","year":"2013","unstructured":"Olsson B, Hertze J, Ohlsson M, N\u00e4gga K, H\u00f6glund K, Basun H, et al. Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer\u2019s disease and vascular dementia. J Alzheimers Dis. 2013;34:673\u20139.","journal-title":"J Alzheimers Dis."},{"key":"276_CR62","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1326-8-39","volume":"8","author":"RS Desikan","year":"2013","unstructured":"Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, et al. Heart fatty acid binding protein and A\u03b2-associated Alzheimer\u2019s neurodegeneration. Mol Neurodegener. 2013;8:39.","journal-title":"Mol Neurodegener."},{"key":"276_CR63","doi-asserted-by":"crossref","first-page":"e995","DOI":"10.1038\/tp.2016.252","volume":"7","author":"K H\u00f6glund","year":"2017","unstructured":"H\u00f6glund K, Kern S, Zettergren A, B\u00f6rjesson-Hansson A, Zetterberg H, Skoog I, et al. Preclinical amyloid pathology biomarker positivity: effects on tau pathology and neurodegeneration. Transl Psychiatry. 2017;7:e995.","journal-title":"Transl Psychiatry."},{"key":"276_CR64","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jamaneurol.2015.1449","volume":"72","author":"DC B\u00e4ckstr\u00f6m","year":"2015","unstructured":"B\u00e4ckstr\u00f6m DC, Eriksson Domell\u00f6f M, Linder J, Olsson B, \u00d6hrfelt A, Trupp M, et al. Cerebrospinal fluid patterns and the risk of future dementia in early, incident Parkinson disease. JAMA Neurol. 2015;72:1175\u201382.","journal-title":"JAMA Neurol."},{"key":"276_CR65","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1750-3639.2009.00369.x","volume":"20","author":"D Aarsland","year":"2010","unstructured":"Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson\u2019s disease. Brain Pathol. 2010;20:633\u20139.","journal-title":"Brain Pathol."},{"key":"276_CR66","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1212\/01.wnl.0000249130.63615.cc","volume":"67","author":"C Ballard","year":"2006","unstructured":"Ballard C, Ziabreva I, Perry R, Larsen JP, O\u2019Brien J, McKeith I, et al. Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology. 2006;67:1931\u20134.","journal-title":"Neurology."},{"key":"276_CR67","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(11)70014-X","volume":"10","author":"B Mollenhauer","year":"2011","unstructured":"Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-D\u00f6ring F, Trenkwalder C, Schlossmacher MG. \u03b1Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 2011;10:230\u201340. A published erratum appears in Lancet Neurol. 2011;10:297.","journal-title":"Lancet Neurol"},{"key":"276_CR68","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry. 2015;86:1240\u20137.","journal-title":"J Neurol Neurosurg Psychiatry."}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-017-0276-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T13:50:07Z","timestamp":1569937807000},"score":1,"resource":{"primary":{"URL":"http:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-017-0276-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,28]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["276"],"URL":"https:\/\/doi.org\/10.1186\/s13195-017-0276-4","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,28]]},"article-number":"52"}}